timothy sykes logo
ImmunityBio Faces Potential Setback Amid Director’s Share Sale and Investigation Thumbnail
ADD US ONG Google News

ImmunityBio Faces Potential Setback Amid Director’s Share Sale and Investigation

TIM SYKES•UPDATED MAR. 10, 2026, 2:33 PM ET
Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs

ImmunityBio Inc.’s stocks have been trading down by -6.04 percent following unfavorable market sentiment from recent news.

Candlestick Chart

Live Update At 14:32:40 EDT: On Tuesday, March 10, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending down by -6.04%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview

In a rollercoaster of market behaviors, the stock price of ImmunityBio, recognized as IBRX, has witnessed both peaks and troughs in recent trading sessions. Starting the week of Mar 4, 2026, with highs above $10 and closing at $10, the value trailed downward by Mar 10 to $7.94. This volatility is partly attributed to internal and external pressures, including shifts in company leadership and market speculations. The quick succession of executive decisions and investigative actions has left traders cautious.

Adding complexity, ImmunityBio’s financial indicators show troubling signs. With profitability margins reflecting substantial negatives – such as an EBIT margin of -278.4% – the company struggles to find its profitable footing. The stock commands attention with a price-to-sales ratio at a staggering 78.68 times its sales. Yet, revenue figures emphasize rough terra firma, with only moderate gains over three and five-year periods respectively. This blend of financial strain and shifting stock prices mandates a significant hurdle for renewed investor confidence.

Market Reactions to Developments

Market reactions to recent events around ImmunityBio reveal a mixture of apprehension and potential. The share sale by Barry J. Simon has not gone unnoticed, stirring worries about internal sentiments towards the company’s future. Historically, sizable insider share divestments hint at foreseen hurdles or shifts, whether strategic or financial. Investors often see such moves as a warning, signaling potential downturns or organizational changes on the horizon.

On the legal front, ImmunityBio is under scrutiny from Pomerantz LLP. The investigation’s timing aligns ominously with unfavorable clinical trial tests, adding another layer of Pomerantz’s interest in the potential wrongdoing. The lack of clarity on Phase 2 trial results, a space where benchmarks hold high stakes, adds uncertainty. The company disclosed that a crucial endpoint in its trial has yet to be reached, sparking assumptions that these facts could have affected share performance as panic drove stock price down.

These unforeseen disclosures can disrupt projected paths. Investors, weighing the risks associated with trial uncertainties and regulatory investigations, might opt for safer harbors till clearer skies appear. As price wobbles continue, market resilience enters the test—a waiting game to see if ImmunityBio can recalibrate or if the slippage deepens.

More Breaking News

Conclusion

ImmunityBio’s current landscape, intertwined with legal challenges and executive decisions, suggests a still-developing narrative. The market’s interpretive dance around these changes poses questions about sustainable growth in a high-stakes medicinal sector. While optimistic eyes search for a turning point, traders remain poised, mindful of potential gains or cautions ahead. As millionaire penny stock trader and teacher Tim Sykes says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” ImmunityBio’s odyssey encompasses a breadth of narratives—revealing fortitude or falterings that will shape its financial legacy.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading IBRX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”